Enliven Therapeutics
ELVN
31 hedge funds and large institutions have $86.3M invested in Enliven Therapeutics in 2021 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 12 reducing their positions, and 16 closing their positions.
0.16% less ownership
Funds ownership: 15.65% → 15.49% (-0.16%)
7% less capital invested
Capital invested by funds: $92.6M → $86.3M (-$6.24M)
23% less funds holding
Funds holding: 40 → 31 (-9)
33% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 12
56% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.1M |
| 2 |
Russell Investments Group
London,
United Kingdom
|
+$1.5M |
| 3 |
Morgan Stanley
New York
|
+$827K |
| 4 |
Renaissance Technologies
New York
|
+$308K |
| 5 |
TEE
Tibra Equities Europe
London,
United Kingdom
|
+$291K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.94M |
| 2 |
State Street
Boston,
Massachusetts
|
-$693K |
| 3 |
DM
Deerfield Management
New York
|
-$671K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$657K |
| 5 |
Two Sigma Investments
New York
|
-$430K |
ELVN Hedge Fund Activity: Q2 2021 in Review
31 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Enliven Therapeutics (ELVN) for Q2 2021, worth a combined $86.3M — down 6.7% from $92.6M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of ELVN and 7 opened new positions — a net loss of 9 holders — while 12 trimmed existing stakes and 8 added.
The largest buyer was Fidelity Investments, adding an estimated $3.1M. The largest seller was BlackRock, cutting an estimated $2.94M.
- 31 institutional investors held Enliven Therapeutics (ELVN) as of Q2 2021, down from 40 in Q1 2021.
- Funds reported $86.3M of Enliven Therapeutics stock for Q2 2021, down 6.7% quarter-over-quarter.
- 7 funds opened new Enliven Therapeutics positions in Q2 2021 and 16 closed out, a net change of -9 holders.
- The largest Enliven Therapeutics buyer in Q2 2021 was Fidelity Investments, an estimated $3.1M added.
- The largest Enliven Therapeutics seller in Q2 2021 was BlackRock, an estimated $2.94M sold.
Based on aggregated 13F filings for Q2 2021.